Geron (GERN) stock
GERN's Quality Score rose 1 point on Fri, Oct 2, to -3.
Follow GERN's trial news. Pro members can get an alert when Geron files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for GERN, and how long its cash lasts
From Geron’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Its trials
Cash runway
The company says its cash lasts through the first quarter of 2026 (8-K, Dec 16, 2025).
Dilution on the horizon
No shelf registration of its own or at-the-market program on file in the last three years.
Insiders
CFO Michelle Robertson sold 9,855 shares on Feb 18.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 25 daysINOInovio Pharmaceuticals
INOINO-3107
- In 36 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 48 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 17% in 3 months, 16% under its 50-day average. Down 40% over 3 years, while the S&P 500 rose 80%.
Down more than its industry: the 90 other stocks in it fell a median 6% over the same 3 months.
−3Long-term trend below a falling 200-day average, down over one year, down over two years
2 more things pulling GERN's score down, for Pro members
What's next
Expected to report Wed Nov 4, before the open
After its last 3 reports it closed -6.9% on average, higher 0 of 3 times.
What would turn GERN's score around: 7 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
GERN has 2 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1432.0
- MACD (12, 26, 9)Below signal
- 50-day average$1.42
- 200-day average$1.45
- ADX 1429.5
- Support$1.19
- Resistance$1.28
- Bollinger Bands (20, 2)Inside
- Volume1.4x
How GERN ranks in Pharma
GERN is #74 of 91 by Quality Score. The top three are shown with their scores, and more by name.
ABBV8/1419
GMAB8/1415
MRK7/1413
EOLSOpen for its score
ERASOpen for its score
GSKOpen for its score
GERN2/14-3
When does GERN report earnings, and what happens after?
Expected to report Wed Nov 4, before the open (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026Before open | Before open | -1.8% | -3.7% | -3.7% |
| Feb 25, 2026Before open | Before open | -13.8% | -11.8% | -26.1% |
| Nov 5, 2025Before open | Before open | -4.3% | -5.2% | +8.7% |
About Geron
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of GERN's score, with the points and the reason
- All 14 checks on GERN and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on GERN
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.